n-(3-(aminomethyl)benzyl)acetamidine has been researched along with Diabetes Mellitus, Type 2 in 1 studies
N-(3-(aminomethyl)benzyl)acetamidine: structure in first source
N-[3-(aminomethyl)benzyl]acetamidine : An aralkylamine that is Nbenzylacetamidine substituted at position 3 on the benzene ring by an aminomethyl group. An inhibitor of nitric oxide synthase.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prolonged glucose treatment caused insulin resistance and several hallmarks of type 2 diabetes." | 1.43 | Interplay between the kinin B1 receptor and inducible nitric oxide synthase in insulin resistance. ( Couture, R; Haddad, Y, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Haddad, Y | 1 |
| Couture, R | 1 |
1 other study available for n-(3-(aminomethyl)benzyl)acetamidine and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Interplay between the kinin B1 receptor and inducible nitric oxide synthase in insulin resistance.
Topics: Amidines; Animals; Benzylamines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Insuli | 2016 |